RxDoctor Payments DataLook up a doctor →

Samer Kassar, MD

Neurology · Dyer, INNPI 1902839525

Payments from drug & device makers

$77,937in general payments, 2019–2025

Across 1,686 payments — averaging $46.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$51K
  • Biogen$5K
  • UCB, Inc.$1K
  • Novartis$1K
  • Lilly USA, LLC$1K
  • Banner Life Sciences, LLC$1K
  • plus $17K from 54 others

What the payments were for

  • Speaking & faculty fees$48,04962%
  • Food & beverage$29,64038%
  • Education$2490%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)294$50,958
Biogen223$4,587
UCB, Inc.86$1,347
Novartis83$1,263
Lilly USA, LLC66$1,235
Banner Life Sciences, LLC17$1,174
AstraZeneca(2 entities)44$1,066
Catalyst Pharmaceuticals, Inc.30$982
Teva Pharmaceuticals USA, Inc.68$760
Eisai Inc.35$711
SK Life Science, Inc.42$704
Livanova USA, Inc.14$645
MDD US Operations, LLC44$626
Jazz Pharmaceuticals Inc.24$611
Sunovion Pharmaceuticals Inc.39$603
EMD Serono, Inc.37$583
Neurocrine Biosciences, Inc.28$560
Bristol Myers Squibb34$541
Argenx US, Inc.26$499
Pfizer59$497
Lundbeck LLC24$493
Sanofi22$404
Johnson & Johnson(2 entities)23$397
CSL Behring17$334
Acorda Therapeutics, Inc16$331
Mallinckrodt Hospital Products Inc.12$325
Amgen17$321
Supernus Pharmaceuticals, Inc.24$303
Genentech USA, Inc.14$289
Saol Therapeutics Inc.5$264
Abbott10$253
Neurelis, Inc.7$245
Vanda Pharmaceuticals Inc.10$243
Merz Pharmaceuticals, LLC10$221
TG Therapeutics, Inc.8$215
Upsher-smith Laboratories LLC16$198
Cequr Corporation1$189
Collegium Pharmaceutical, Inc.12$184
Takeda Pharmaceuticals U.S.A., Inc.8$173
Avanir Pharmaceuticals, Inc.6$173
Amneal Pharmaceuticals LLC10$168
Grifols USA, LLC7$155
Acadia Pharmaceuticals Inc9$155
Medtronic(2 entities)7$148
E.r. Squibb & Sons, L.L.C.8$140
Harmony Biosciences LLC6$133
GRT US Holding, Inc.2$125
Corium, LLC12$110
Arbor Pharmaceuticals, Inc.7$83
Alnylam Pharmaceuticals Inc.4$82
Dexcom, Inc.1$75
Sumitomo Pharma America, Inc.5$74
Currax Pharmaceuticals LLC5$71
Biohaven Pharmaceuticals, Inc.4$55
Mallinckrodt Enterprises LLC3$53
Octapharma USA, Inc.2$51
Ipsen Biopharmaceuticals, Inc2$50
Cycle Pharmaceuticals Inc2$47
Biohaven Pharmaceutical Holding Company Ltd.3$44
Aucta Pharmaceuticals, Inc.2$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,937 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$501,867
Medicare patients
893
Services billed
23,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$667,564
Gamunex-CImmune Globul G/Gly/Iga Avg 4632$221,590
QuliptaAtogepant72$99,752
Emgality PenGalcanezumab-Gnlm53$40,073
UbrelvyUbrogepant38$39,674
Aimovig AutoinjectorErenumab-Aooe25$24,882
FycompaPerampanel19$19,705
BriviactBrivaracetam11$18,400
Nurtec OdtRimegepant Sulfate13$18,036
Oxtellar XrOxcarbazepine15$17,675
XcopriCenobamate11$13,883
Lacosamide55$13,875
Levetiracetam116$4,880
Memantine Hcl171$4,206
RivastigmineRivastigmine Tartrate62$3,577

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$1,066$667,56413 claims
Grifols USA, LLCGamunex-C$155$221,59032 claims
AbbVieQulipta, Ubrelvy$50,958$139,426110 claims
Eisai Inc.Fycompa$711$19,70519 claims
UCB, Inc.Briviact$1,347$18,40011 claims
PfizerNurtec Odt$497$18,03613 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$303$17,67515 claims
SK Life Science, Inc.Xcopri$704$13,88311 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$168$1,21319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →